Merck (known as MSD outside the U.S. and Canada) will collaborate with MSD South Africa and Adcock Ingram to co-promote and distribute a number of established MSD products in South Africa. These products include OTC products and selected prescription medicines currently registered in South Africa by MSD and Schering-Plough.
MSD entered into the collaboration with Adcock Ingram to co-promote and distribute products from various therapeutic areas including asthma, dermatology, hypercholesterolemia, hypertension, migraine, and osteoporosis as well as a portfolio of OTC medications.
“We are excited about the collaboration with MSD because it will enhance our diverse portfolio and broaden our pipeline of new products in the marketplace,” says Jonathan Louw, CEO of Adcock Ingram.
Merck expects that emerging markets will account for more than 25% of its global pharmaceutical and vaccine revenue in 2013. The company intends to continue launching new products, optimize its in-line portfolio of medicines, vaccines, follow-on biologics, and consumer-care products, and fully leverage the market for branded generics with the company’s portfolio of mature brands as well as targeted business development.